Brought to you by 
J&J will acquire Tibotec-Virco NV
Mar 2002
Executive Summary
Johnson & Johnson has agreed to acquire all the assets of Tibotec-Virco NV, a closely held biotech with diagnostics and clinical-phase drugs in HIV and other viral diseases. J&J will pay about $320mm in cash and assumed debt.
Deal Industry
-
Biotechnology
-
Drug Discovery Tools
- Molecular Diversity
-
Drug Discovery Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
J&J will acquire Tibotec-Virco NV
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice